Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2 ...
Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five ...
The average one-year price target for Travere Therapeutics (NasdaqGM:TVTX) has been revised to $50.45 / share. This is an ...
In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Merck & Company, with a price target of $140.00. Claim 55% Off TipRanks. Unlock hedge fund-l ...
Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA medicines, today announced it will present preclinical data from its in vivo CAR-T program at the 2026 American ...
Johnson & Johnson will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026.
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will ...
Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential as progresses ...
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc.
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In ...
An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...
"AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data" was originally created and published by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results